Cingulate Inc (CING) Actualités

Final Study Completed for Cingulate’s Lead Asset CTx-1301

No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan...

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc...

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Cingulate Announces Adjournment of Special Meeting

KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the...